Reinbek - Allergopharma, the allergy business of Merck, has received the seal “Innovation through Research” from the “Stifterverband” (Donors' Association for German Science e.V.) for the second time. The award is given to companies that show a special commitment to research and development. The precondition is that they document their research activities by participating in a survey on their research and development activities. “We are pleased about the new seal from the ‘Stifterverband’. For over 50 years, we have been conducting research in close collaboration with physicians and scientists and develop solutions for the effective treatment of allergies,” explains Marco Linari, Chief Executive Officer of Allergopharma. “With long-standing expertise, scientific excellence and entrepreneurial responsibility, we do our utmost to provide physicians with first-class therapy options and help people with allergies lead more fulfilled lives.”
Since 2014, the “Stifterverband” has awarded the seal “Innovative through Research” in recognition of the special responsibility that companies assume for the state of Germany and the society. Allergopharma was awarded again after 2016 and bears the seal until the end of 2019.
About the “Stifterverband” (Donors' Association for German Science e.V.)
The “Stifterverband” is one of the largest private science sponsors in Germany. In addition to its commitment to young academics, excellent universities and cutting-edge research, its task is also to examine and evaluate the German research and innovation system.